STOCK TITAN

Aravive, Inc. - $ARAV STOCK NEWS

Welcome to our dedicated page for Aravive news (Ticker: $ARAV), a resource for investors and traders seeking the latest updates and insights on Aravive stock.

Aravive, Inc. (Nasdaq: ARAV) is a late clinical-stage oncology company committed to developing targeted therapeutics for the treatment of metastatic diseases. With its headquarters in Houston, Texas, the company is at the forefront of cancer research aiming to improve the quality of life and outcomes for patients battling severe forms of cancer.

The company's lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein designed to inhibit AXL receptor signaling by binding to its ligand GAS6. This mechanism is intended to prevent tumor growth and metastasis, as well as to restore sensitivity to existing anti-cancer therapies. Batiraxcept has received Fast Track Designation from the U.S. FDA for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer, along with Orphan Drug Designation from the European Commission for platinum-resistant recurrent ovarian cancer.

Despite recent challenges, such as the Phase 3 AXLerate-OC trial not meeting its primary endpoint in platinum-resistant ovarian cancer, Aravive remains committed to analyzing the complete dataset and determining the next steps for their other indications in renal cell carcinoma and pancreatic cancer. The Phase 3 trial involved 366 patients and aimed to evaluate the efficacy and safety of batiraxcept in combination with paclitaxel.

Aravive collaborates with renowned research groups, including The GOG Foundation, Inc. in the U.S. and the European Network for Gynecological Oncological Trials (ENGOT) in Europe. Funded by a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016, the company continues to innovate in the field of oncology.

For more information on their ongoing research and development efforts, please visit their website at www.aravive.com.

Rhea-AI Summary
Aravive, Inc. (Nasdaq: ARAV) has announced its intention to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market and deregister its common stock under the Securities Exchange Act of 1934. This decision follows the approval of effecting a transfer and assignment of all or substantially all of the Company’s assets to an assignee for the benefit of creditors and the dissolution and liquidation of the Company. The Company's non-compliance with the Minimum MVLS Requirement, Minimum MVPHS Requirement, and Minimum Bid Price Requirement has led to this decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.45%
Tags
none
-
Rhea-AI Summary
Aravive's Phase 3 AXLerate-OC trial for batiraxcept in ovarian cancer did not meet primary endpoint of progression-free survival. Cash at end of Q2 is $18M, expected to fund operations into early Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-77.25%
Tags
-
Rhea-AI Summary
Aravive announces acceptance of two abstracts for poster presentation at ESMO Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.22%
Tags
conferences clinical trial
Rhea-AI Summary
Aravive, Inc. announced that its CEO, Gail McIntyre, will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success on July 18, 2023. The event will be held virtually and a replay will be available for 7 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.47%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences
Rhea-AI Summary
Aravive, Inc. announces updated results from its Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 ASCO annual meeting. The results support the potential of batiraxcept plus cabozantinib combination therapy in ccRCC patients. A Phase 3 trial is planned to initiate in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.48%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
Rhea-AI Summary
Aravive reports Q1 2023 financial results and provides corporate updates, including progress in the development of batiraxcept in ovarian, kidney, and pancreatic cancer. The company remains on track for topline results from its platinum-resistant ovarian cancer (PROC) Phase 3 trial in mid-2023. Carolina Petrini has been appointed as Chief Commercial Officer. Updated data from the clear cell renal cell carcinoma (ccRCC) trial will be presented at ASCO 2023. Batiraxcept has been granted FDA Orphan Drug Designation in pancreatic cancer. Cash and cash equivalents as of March 31, 2023, were $35.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences

FAQ

What is Aravive, Inc.?

Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic diseases.

What is batiraxcept?

Batiraxcept is Aravive's lead product candidate, an ultra-high affinity decoy protein designed to inhibit AXL receptor signaling by binding to its ligand GAS6.

What designations has batiraxcept received?

Batiraxcept has received Fast Track Designation from the U.S. FDA for clear cell renal cell carcinoma and platinum-resistant ovarian cancer, and Orphan Drug Designation from the European Commission for platinum-resistant recurrent ovarian cancer.

What was the outcome of the AXLerate-OC Phase 3 trial?

The AXLerate-OC Phase 3 trial did not meet its primary endpoint of progression-free survival in platinum-resistant ovarian cancer. Aravive is conducting further analyses to determine next steps.

Where is Aravive, Inc. based?

Aravive, Inc. is headquartered in Houston, Texas.

Who are Aravive's research partners?

Aravive collaborates with The GOG Foundation, Inc. in the U.S. and the European Network for Gynecological Oncological Trials (ENGOT) in Europe.

What is Aravive’s mission?

Aravive's mission is to develop innovative cancer treatments that can significantly improve patient outcomes and quality of life.

How is Aravive funded?

In 2016, Aravive received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT).

How can I find more information about Aravive?

More information about Aravive, Inc. can be found on their website at www.aravive.com.

What kind of cancer indications is Aravive focusing on?

Aravive is focusing on indications such as platinum-resistant ovarian cancer, renal cell carcinoma, and pancreatic cancer.

Aravive, Inc.

Nasdaq:ARAV

ARAV Rankings

ARAV Stock Data

2.95M
45.08M
38.69%
8.21%
1.81%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Houston